After AbbVie earlier this year pledged a whopping $100 billion in U.S. R&D and capital investments over the next decade, the ...
As pharma giants slash headcounts and routinely strike billion-dol | Amid industry layoffs and M&A headlines, Big Pharma's ...
In the merger of the New Jersey-based neighbors who conduct much of their manufacturing in India, generics leader Amneal is ...
Samsung Bio is bringing its financial hot streak into 2026, with no signs of stopping—save for a potential worker strike ...
Novartis is running a new disease awareness campaign for Sjögren's syndrome with help from dancer, choreographer, and TV personality Carrie Ann Inaba. | Novartis is running a new disease awareness ...
The era of off-label guesswork for patients living with the rare autoimmune disorder MOGAD may soon be over, as a phase 3 ...
Merck is carving out its own place in the evolving HIV treatment space with an FDA approval for its Idvynso, a combination ...
Pfizer’s chief strategist, Andrew Baum, M.D., is leaving his post two years after pivoting from a career-long tenure as a ...
With the recent launches of Novo Nordisk’s Wegovy pill and Eli Lilly’s Foundayo, the obesity market has started to shift ...
After prevailing in two kidney cancer trials in the refractory and early-stage settings, Merck & Co.’s blockbuster prospect ...
Sanofi’s protein-based vaccine Nuvaxovid has conquered Moderna’s next-generation messenger RNA shot mNexspike in a ...
Already approved to treat four rare diseases, AstraZeneca’s Ultomiris has shown its ability against another rare disorder, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results